RedShift™ BioAnalytics has launched the AQS3™pro, a new protein characterisation platform with integrated bioanalytics software that provides automated, sensitive spectroscopic analysis for the development, formulation and manufacture of biotherapeutics. Its ability to provide multiple attribute data reduces or eliminates the need to perform separate measurements across different tools. The AQS3pro uses the patented technique of microfluidic modulation spectroscopy (MMS) which combines mid-infrared laser spectroscopy with microfluidics and advanced signal processing to measure the secondary structure of proteins. It provides direct, label-free measurements over the concentration range 0.01–200 mg mL–1, characterising samples under all the conditions routinely encountered in biopharmaceutical development and manufacture, without sample dilution. Measurement is automated, by multi-sample, walk-away operation and state-of-the-art bioanalytics software. The flexible analytics suite automates the routine analysis of spectroscopic data, and provides tools for gaining insights into structural change and its implications.
